OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
SOUTH SAN FRANCISCO, Calif., May 25, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Jefferies 2017 Global Healthcare Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on June 7, 2017, at 3:00 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform. The Company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and develop first-in-class cancer therapeutics against difficult-to-drug targets, such as CD166. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The Company’s lead program, CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is being evaluated in a Phase 1/2 study. CX-072 is part of PROCLAIM (Probody Clinical Assessment In Man), an international umbrella clinical trial program that provides clinical trial sites with access to the Company’s novel therapies under one central protocol. The trial initiation for CX-2009, a first-in-class Probody drug conjugate targeting the highly expressed tumor antigen, CD166, is expected mid-2017. In addition to its proprietary programs, CytomX is collaborating with strategic partners, including AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact: Canale Communications Ian Stone [email protected] 619-849-5388 Investor Contact: Trout Group Pete Rahmer [email protected] 646-378-2973
